CSL Ltd (ASX: CSL) shares are down 1.08% to $261.40 per share on Thursday.
It's a red day for the broader market, too, with the S&P/ASX 200 Index (ASX: XJO) down 0.6%.
Next Monday, CSL shares will begin trading ex-dividend.
That means investors have only today and tomorrow to scoop up some CSL shares to qualify for the next dividend payment.
CSL shares will pay a 9% higher interim dividend of US$1.30 per share unfranked on 9 April.
Australian investors will receive their CSL dividend in AU dollars.
Based on the exchange rate at the time, CSL will confirm the interim dividend amount in AU terms next Thursday.
How did CSL's 1H FY25 results look?
Last month, CSL reported a 5% increase in constant currency revenue to US$8.48 billion and a 7% increase in net profit after tax (NPAT) in constant currency terms to US$2.04 billion.
The main driver of overall revenue growth was the CSL Behring division.
CSL Behring manufactures medicines for many illnesses and operates one of the world's largest plasma collection networks.
CSL reported a 10% lift in Behring division revenue to US$5.74 billion.
This reflected a 15% jump in immunoglobulin product sales to US$3,174 million, a 9% increase in Albumin sales to US$672 million, and an 11% rise in Haemophilia sales to US$731 million.
Offsetting some of this was a 5% drop in specialty product sales. CSL added that its plasma collections grew while the cost of collections fell.
The CSL Seqirus business, which develops and manufactures vaccines, recorded a 9% decline in sales to US$1.66 billion. This partly reflects a global trend in lower immunisation rates.
Sales in CSL's Vifor division, which develops and manufactures pharmaceuticals to treat iron deficiency and kidney disease, rose by 6% to US$1.08 billion.
This was driven by rising demand for iron products in Europe and higher demand for Tavneos, a drug that treats inflammatory conditions of the blood vessels, across all markets.
CSL shares snapshot
The CSL share price has fallen by just over 7% in the year to date.
The day before the 1H FY25 results were released, CSL shares hit a 52-week low of $253.04.
Goldman Sachs has a buy rating on CSL shares with a 12-month price target of $318.40.
The consensus rating among analysts on the CommSec trading platform is a strong buy.
